Upstream Bio, Inc. (UPB NASDAQ) stock market data APIs
$11.5102
0.2(1.7%)
as of July 11, 2025
Try our APIs with
free plan!
Upstream Bio, Inc. Financial Data Overview
Price chart is built with
Anychart
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Prev. Close
11.5102
Open
11.7113
High
11.8712
Low
11.4882
52 wk Range
5.14-29.46
Market Cap
407 M
Shares Outstanding
53 597 K
Revenue
2 207 K
EPS
-0.51
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Upstream Bio, Inc. data using free add-ons & libraries
Get Upstream Bio, Inc. Fundamental Data
Upstream Bio, Inc. Fundamental data includes:
- Net Revenue: 2 207 K
- EBITDA: -65 722 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.48
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Upstream Bio, Inc. News
New
Upstream Bio begins phase 2 COPD trial for verekitug
WALTHAM, Mass. - Upstream Bio, Inc. (NASDAQ:UPB) has dosed the first patient in its Phase 2 clinical trial evaluating verekitug for chronic obstructive pulmonary disease (COPD), the company announced ...
Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program f...
Translational Data Illustrate a Mechanism of Greater Potency with Verekitug, a Novel Antibody Antagonist of the TSLP Receptor
“ Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI) Congress describe mechanistic insights for greater potency with verekitug compared to tezepelu...
Upstream Bio Presents Pharmacology Modeling Data Supporting Verekitug's Potency over Tezepelumab at EAACI Congress
Upstream Bio presents data suggesting verekitug offers greater potency than tezepelumab in targeting inflammatory diseases. Quiver AI Summary Upstream Bio, Inc. presented data at the European Academ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
